By DrBicuspid Staff

July 11, 2016 -- Vigilant Biosciences has raised $5 million to commercialize OncAlert, its oral cancer detection test.

Vigilant has received $12.5 million in total funding, including most recently a round of $5 million in Series B funding. The proceeds will be used for the international commercialization of OncAlert and to continue the company's research and development efforts.

Vigilant to launch oral cancer rinse test
Vigilant Biosciences will launch an oral rinse test for oral cancer at the American Society of Clinical Oncology (ASCO) 2016 annual meeting in Chicago.
Vigilant creates new clinical officer position
Vigilant Biosciences has appointed Michael Donovan, MD, PhD, as the its new chief clinical officer.
Vigilant gets CE Mark for 2nd oral cancer test
Vigilant Biosciences' OncAlert oral cancer rapid test has received the CE Mark, which allows the company to market the test in Europe.
Vigilant gets CE Mark for oral cancer test
Vigilant Biosciences' OncAlert oral cancer CD44/total protein lab test has received the CE Mark, which allows the company to market the test in Europe.
Vigilant gets $2.3M for oral cancer test
Vigilant Biosciences has received $2.3 million to develop its "rinse and spit" test for the early detection of oral cancer.

Copyright © 2016 DrBicuspid.com